RU2019136694A - Фенил-2-гидрокси-ацетиламино-2-метил-фениловые соединения - Google Patents
Фенил-2-гидрокси-ацетиламино-2-метил-фениловые соединения Download PDFInfo
- Publication number
- RU2019136694A RU2019136694A RU2019136694A RU2019136694A RU2019136694A RU 2019136694 A RU2019136694 A RU 2019136694A RU 2019136694 A RU2019136694 A RU 2019136694A RU 2019136694 A RU2019136694 A RU 2019136694A RU 2019136694 A RU2019136694 A RU 2019136694A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- pharmaceutically acceptable
- methyl
- acceptable salt
- phenyl
- Prior art date
Links
- -1 PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- HLLGQFADOTVZQN-LJQANCHMSA-N (2R)-N-[4-(4-amino-7-methylpyrrolo[2,3-d]pyrimidin-5-yl)-3-methylphenyl]-2-(3-fluorophenyl)-2-hydroxyacetamide Chemical compound NC=1C2=C(N=CN=1)N(C=C2C1=C(C=C(C=C1)NC([C@H](O)C1=CC(=CC=C1)F)=O)C)C HLLGQFADOTVZQN-LJQANCHMSA-N 0.000 claims 1
- BRIWRAFDHZTJPE-OAQYLSRUSA-N 2-amino-5-[4-[[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]amino]-2-methylphenyl]-N-propan-2-ylpyridine-3-carboxamide Chemical compound NC1=NC=C(C=C1C(=O)NC(C)C)C1=C(C=C(C=C1)NC([C@H](O)C1=CC(=CC(=C1)F)F)=O)C BRIWRAFDHZTJPE-OAQYLSRUSA-N 0.000 claims 1
- WFLLOUGNTSBEON-GOSISDBHSA-N 3-amino-6-[4-[[(2R)-2-(3,5-difluorophenyl)-2-hydroxyacetyl]amino]-2-methylphenyl]-N-methylpyrazine-2-carboxamide Chemical compound NC=1C(=NC(=CN=1)C1=C(C=C(C=C1)NC([C@H](O)C1=CC(=CC(=C1)F)F)=O)C)C(=O)NC WFLLOUGNTSBEON-GOSISDBHSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
- C07D241/28—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms in which said hetero-bound carbon atoms have double bonds to oxygen, sulfur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Claims (39)
1. Соединение формулы
где
R выбран из группы, состоящей из
X представляет собой CH или N;
R1 представляет собой водород или фтор; и
R2 представляет собой С1-С3 алкил;
или его фармацевтически приемлемая соль.
2. Соединение по п.1 формулы
где
R выбран из группы, состоящей из
X представляет собой CH или N;
R1 представляет собой водород или фтор; и
R2 представляет собой С1-С3 алкил;
или его фармацевтически приемлемая соль.
3. Соединение или соль по п. 1 или 2, где R представляет собой
4. Соединение или соль по п. 1 или 2, где
X представляет собой CH или N;
R1 представляет собой водород или фтор; и
R2 представляет собой метил или изопропил.
5. Соединение или соль по п. 1 или 2, где R представляет собой
6. Соединение по п.1 или 2, которое представляет собой 3-амино-6-[4-[[(2R)-2-(3,5-дифторфенил)-2-гидрокси-ацетил]амино]-2-метил-фенил]-N-метил-пиразин-2-карбоксамид, которое может быть представлено формулой
или его фармацевтически приемлемая соль.
7. Соединение по п. 1 или 2, которое представляет собой 2-амино-5-[4-[[(2R)-2-(3,5-дифторфенил)-2-гидрокси-ацетил]амино]-2-метил-фенил]-N-изопропил-пиридин-3-карбоксамид, которое может быть представлено формулой
или его фармацевтически приемлемая соль.
8. Соединение по п. 1 или 2, которое представляет собой (2R)-N-[4-(4-амино-7-метил-пирроло[2,3-d]пиримидин-5-ил)-3-метил-фенил]-2-(3-фторфенил)-2-гидрокси-ацетамид, которое может быть представлено формулой
или его фармацевтически приемлемая соль.
9. Фармацевтическая композиция, содержащая соединение или его фармацевтически приемлемую соль по любому из пп. 1-8 с одним или несколькими фармацевтически приемлемыми носителями, разбавителями или эксципиентами.
10. Способ лечения рака поджелудочной железы у пациента, включающий введение нуждающемуся в этом пациенту эффективного количества соединения по любому из пп.1-8 или его фармацевтически приемлемая соль.
11. Соединение или его фармацевтически приемлемая соль по любому из пп. 1-8 для применения в терапии.
12. Соединение или его фармацевтически приемлемая соль по любому из пп. 1-8 для применения при лечении рака поджелудочной железы.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382207.3 | 2017-04-18 | ||
| EP17382207 | 2017-04-18 | ||
| PCT/US2018/027005 WO2018194885A1 (en) | 2017-04-18 | 2018-04-11 | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2019136694A true RU2019136694A (ru) | 2021-05-18 |
| RU2019136694A3 RU2019136694A3 (ru) | 2021-05-19 |
| RU2804280C2 RU2804280C2 (ru) | 2023-09-26 |
Family
ID=
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220263T1 (hr) | Fenil-2-hidroksi-acetilamino-2-metil-fenil spojevi | |
| MX2025001995A (es) | Compuesto heterociclico, procedimiento para prepararlo y uso farmaceutico del mismo | |
| RU2019106484A (ru) | Гетероциклическое соединение | |
| JP2022141835A5 (ru) | ||
| RU2017116197A (ru) | 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 для лечения болезни альцгеймера | |
| RU2018111439A (ru) | Новое пиразоло[3, 4-d]пиримидиновое соединение или его соль | |
| KR960014123A (ko) | 아미노(티오)에테르 유도체 | |
| MX2021000148A (es) | Inhibidores eterociclicos de erk1 y erk2 y su uso en el tratamiento del cancer. | |
| NZ700761A (en) | Salt form of a human histone methyltransferase ezh2 inhibitor | |
| FI3681857T3 (fi) | Fluorifenyyli-beeta-hydroksietyyliamiineja ja niiden käyttö hyperglykaemian hoidossa | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| RU2015123499A (ru) | Соединения замещенной триазолбороновой кислоты | |
| RU2016105581A (ru) | Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться | |
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| RU2011112948A (ru) | Способы лечения рака с использованием ингибиторов киназ | |
| RU2018147263A (ru) | Фторированные 2-амино-4-(замещенные амино)фенилкарбаматные производные | |
| RU2016134751A (ru) | Соединения | |
| EA202090977A1 (ru) | Новая комбинация активных агентов для лечения прогрессирующих фиброзирующих интерстициальных заболеваний легких (pf-ild) | |
| RU2013150861A (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний | |
| RU2013141559A (ru) | Способ ингибирования клеток опухоли гамартомы | |
| RU2017145930A (ru) | МОДУЛЯТОРЫ ROR ГАММА (RORγ) | |
| RU2017120217A (ru) | 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1 | |
| RU2015137298A (ru) | Ингибиторы тирозинкиназы брутона | |
| RU2017117566A (ru) | Активатор kcnq2-5 каналов | |
| RU2019100037A (ru) | Способ лечения рассеянного склероза с использованием ингибитора lsd1 |